BioLife Solutions Shares Edge Lower On Latest SEC Disclosures
BioLife Solutions shares dropped late Thursday in U.S. trading, underperforming other biotech names, after the cell-therapy tools company published a new investor deck and Casdin Capital revealed a big stake. The Nasdaq stock traded at $27.09, off 17 cents, or 0.6%. The SPDR S&P Biotech ETF was up around 2.7%. BioLife Solutions is aiming to steer investors toward a 2026 growth story, after shifting its portfolio to cell processing products. The company, based in Bothell, Washington, filed a June 3 Form 8-K, telling investors the latest presentation could be used at the Jefferies Global Healthcare Conference or in meetings with investors and analysts.